miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib.

miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton’s tyrosine kinase inhibition with Ibrutinib

[1]  T. Kipps,et al.  MicroRNAs and B cell receptor signaling in chronic lymphocytic leukemia , 2013, Leukemia & lymphoma.

[2]  Jeffrey A Jones,et al.  A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. , 2012 .

[3]  Lisa L. Smith,et al.  Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). , 2014, Blood.

[4]  Jeffrey A Jones,et al.  Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. , 2014, Blood.

[5]  S. Kauppinen,et al.  LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas. , 2012, Blood.

[6]  Jeffrey A Jones,et al.  Association of disease progression on ibrutinib therapy with the acquisition of resistance mutations: A single-center experience of 267 patients. , 2014 .

[7]  Michael Hallek,et al.  Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment , 2013, American journal of hematology.

[8]  T. Elton,et al.  Regulation of the MIR155 host gene in physiological and pathological processes. , 2013, Gene.

[9]  P. Guglielmelli,et al.  Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. , 2014, Blood.

[10]  Adrian Wiestner,et al.  ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. , 2003, Blood.

[11]  J. Byrd,et al.  Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Ferracin,et al.  MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia , 2010, Molecular Cancer.

[13]  Jeffrey A Jones,et al.  Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. , 2011, Blood.

[14]  Muller Fabbri,et al.  A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. , 2005, The New England journal of medicine.

[15]  Wayne Tam,et al.  Accumulation of miR-155 and BIC RNA in human B cell lymphomas. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[16]  L. Packer.  Physiological and pathological processes , 1996 .

[17]  Emanuela M. Ghia,et al.  MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. , 2014, Blood.

[18]  M. Cazzola,et al.  Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia. , 2014, Blood.

[19]  Stefano Volinia,et al.  Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Byrd,et al.  Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). , 2003, Blood.

[21]  Juthamas Sukbuntherng,et al.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. , 2013, The New England journal of medicine.